Carcinoid Tumor Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies – Amgen, Novartis

September 14 00:09 2023
Carcinoid Tumor Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies - Amgen, Novartis
DelveInsight Business Research LLP
DelveInsight’s “Carcinoid Tumor Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Carcinoid Tumor, historical and forecasted epidemiology as well as the Carcinoid Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Carcinoid Tumor Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Carcinoid Tumor, historical and forecasted epidemiology as well as the Carcinoid Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Highlights for Carcinoid Tumor 

  • Key Companies working in the Carcinoid Tumor Market are Amgen, Novartis AG, Exelixis, AVEO Pharmaceuticals, Boehringer Ingelheim GmbH, Aegis Therapeutics, Chiasma, Delcath Systems Inc.

  • Key Therapies included in the Carcinoid Tumor market are as follows Lutathera,  Paltusotine, Octreotide, Everolimus, and many others 

  • The Market size for the Carcinoid Tumor market is USD XX million in 2022 and is projected to increase during the forecast period (2023–2032).

  • The CAGR for the Carcinoid Tumor market is XX%.

Carcinoid Tumor Overview

Carcinoid tumors are a type of slow-growing cancer that can arise in several places throughout your body. Carcinoid tumors, which are one subset of tumors called neuroendocrine tumors, usually begin in the digestive tract (stomach, appendix, small intestine, colon, rectum) or in the lungs.

Carcinoid Tumor is a type of slow-growing cancer that can arise in many places throughout the body & is characterized by the production of an excess of hormonal substances, such as serotonin, bradykinin, histamine, & prostaglandins which leads to other complications. Carcinoid tumors, are the subset of neuroendocrine tumors and usually begin in the digestive tract (small intestine, colon, stomach, appendix, and rectum) or in the lungs. On the basis of their location of origin, these tumors are categorized into three areas as Foregut: The foregut includes the lungs and the stomach; Midgut: comprised of the small intestine, appendix, and the beginning of the large bowel (colon), and Hindgut: composed of the end of the large bowel, the rectum and the organs of the genitourinary tract.

Carcinoid Tumor Epidemiology Insights 

  • Carcinoids are the most common neuroendocrine tumors, with an estimated 1.5-1.9 clinical cases per 100,000 population. The incidence of autopsy cases is higher at 650 cases per 100,000 population.

  • The average age of people diagnosed with GI carcinoid tumors is the early 60s. Carcinoid tumors are more common in African Americans than in White people and are slightly more common in women than men.

Click here to learn more about the Carcinoid Tumor Market Landscape

The Report Covers the Carcinoid Tumor Epidemiology Segmented by:

  • Carcinoid Tumor prevalent cases 

  • Carcinoid Tumor incident cases 

  • Carcinoid Tumor treatment cases 

  • Carcinoma-diagnosed cases 

Carcinoid Tumor Market Outlook

The Carcinoid Tumor market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Carcinoid Tumor market trends by analyzing the impact of current Carcinoid Tumor therapies on the market, unmet needs, drivers and barriers, and demand for better technology. 

This segment gives a thorough detail of the Carcinoid Tumor market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Carcinoid Tumor market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Carcinoid Tumor market in 7MM is expected to witness a major change in the study period 2019-2032.

 Key Companies Working in the Carcinoid Tumor Market

  • Amgen Inc.

  • Novartis AG

  • Exelixis, Inc.

  • AVEO Pharmaceuticals, Inc.

  • Boehringer Ingelheim GmbH

  • Aegis Therapeutics, LLC

  • Chiasma, Inc.

  • Delcath Systems Inc.

And many others 

 Carcinoid Tumor Therapies Covered and Analyzed in the Repor

  • SMT487

  • Lutathera

  • Bevacizumab

  •  Pasireotide

And many others 

Learn more about the Key Companies and Emerging Therapies in the Carcinoid Tumor Market

Table of Contents 

  1. Key Insights 

  2. Carcinoid Tumor Introduction 

  3. Executive Summary of Carcinoid Tumor       –     

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Carcinoid Tumor Emerging Therapies

  7. Carcinoid Tumor Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Market Drivers 

  10. Market Barriers 

  11. Appendix

  12. Report Methodology

  13. DelveInsight Capabilities

  14. Disclaimer

Learn about the detailed offerings of the report @ Carcinoid Tumor Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services